Romidepsin selectively inhibits HDAC1/2, modulates the Treg/Th1 balance in the tumor microenvironment, and significantly suppresses CRC progression when combined with immune checkpoint inhibitors (ICIs) [144]. Here, HDAC1 is linked to colorectal carcinoma.